Morgan Stanley Starts ADARx Pharmaceuticals (ADRX) at Overweight

October 20, 2026 3:50 AM EDT Send to a Friend
Morgan Stanley analyst Michael E Ulz initiates coverage on ADARx Pharmaceuticals (NASDAQ: ADRX) with a Overweight rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login